
    
      This will be a single center, open study in children (aged 1 to 5 years) and vaccine-naïve
      infants, as follows: 50 OPV-vaccinated children aged 1 to 5 years to receive 1 dose of tOPV
      (Group 1); 104 vaccine-naïve infants to receive 3 doses of tOPV administered 28 days apart
      (Group 2)
    
  